Skip to main content
SpringerLink
Log in

Le diagnostic de la leucémie myéloïde chronique (LMC) en 2012

Chronic myeloid leukemia (CML) diagnosis in 2012

  • Mise au Point / Update
  • Published:
Oncologie

Abstract

Diagnosis of Chronic myeloid leukemia (CML), a myeloproliferative neoplasia, as well as the assessment of evolutive phase and prognostic score demands: 1) a clinical examination with spleen measurement; 2) blood counts showing hyperleucocytosis with basophilia and immature granulocytic cells at various stages of differentiation; 3) a bone marrow aspirate exhibiting excess of cells belonging to the granulocytic lineage; 4) a karyotype and/or FISH identifying the Philadelphia chromosome, a (9;22) translocation, and/or the fusion gene BCR-ABL1, which codes for the tyrosinekinase protein responsible for the disease; and 5) a polymerase chain reaction (PCR) characterizing the BCR-ABL1 fusion transcript both on qualitative and quantitative basis.

Résumé

Le diagnostic de la néoplasie myéloproliférative que représente la LMC, ainsi que la détermination de sa phase évolutive et de son score pronostique nécessitent: 1) un examen clinique mesurant l’éventuelle splénomégalie; 2) un hémogramme retrouvant une hyperleucocytose avec basophilie et myélémie harmonieuse; 3) unmyélogramme montrant une hyperplasie granulocytaire; 4) un caryotype médullaire et/ou FISH identifiant le chromosome de Philadelphie par translocation (9;22) et/ou le gène de fusion BCR-ABL1 codant pour la protéine tyrosine-kinase à l’origine de la maladie; 5) un polymerase chain reaction (PCR) caractérisant qualitativement et quantitativement le transcrit de fusion BCR-ABL1.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Baccarani M, Saglio G, Goldman J, et al. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809–1820

    Article  PubMed  CAS  Google Scholar 

  2. Breccia M, Cannella L, Diverio D, et al. (2008) Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. Leuk Res 32(1): 177–180

    Article  PubMed  CAS  Google Scholar 

  3. Brenner H, Gondos A, Pulte D (2008) Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica 93(10): 1544–1549

    Article  PubMed  Google Scholar 

  4. Burmeister T, Reinhardt R (2008) A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 32(4): 579–585

    Article  PubMed  CAS  Google Scholar 

  5. Christoforidis JB, DeAngelo DJ, D’Amico DJ (2003) Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. Am J Ophthalmol 135(3): 398–400

    Article  PubMed  CAS  Google Scholar 

  6. Corm S, Roche L, Micol JB, et al. (2011) Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukaemia over 1990-2007: a population study. Blood 118(16): 4331–4337

    Article  PubMed  CAS  Google Scholar 

  7. Daley G, Van Etten R, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824–830

    Article  PubMed  CAS  Google Scholar 

  8. Druker B, Talpaz M, Resta D, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine-kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037

    Article  PubMed  CAS  Google Scholar 

  9. Garypidou V, Vakalopoulou S, Dimitriadis D, et al. (2004) Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica 89(2): 245–246

    PubMed  Google Scholar 

  10. Goldman J, Melo J (2003) Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 349: 1451–1464

    Article  PubMed  CAS  Google Scholar 

  11. Hasford J, Baccarani M, Hoffmann V, et al. (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2,060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3): 686–692

    Article  PubMed  CAS  Google Scholar 

  12. Hasford J, Pfirrmann M, Hehlmann R, et al. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11): 850–858

    Article  PubMed  CAS  Google Scholar 

  13. Heisterkamp N, Jenster G, ten Hoeve J, et al (1990) Acute leukaemia in BCR/ABL transgenic mice. Nature 344: 251–253

    Article  PubMed  CAS  Google Scholar 

  14. Heisterkamp N, Stephenson J, Groffen J, et al. (1983) Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306: 239–242

    Article  PubMed  CAS  Google Scholar 

  15. Lugo T, Pendergast A, Muller A, Witte O (1990) Tyrosine-kinase activity and transformation potency of BCR-ABL oncogene products. Sience 247: 1079–1082

    Article  CAS  Google Scholar 

  16. Millot F, Traore P, Guilhot J, et al. (2005) Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116(1): 140–143

    Article  PubMed  Google Scholar 

  17. Nowell P, Hungerford D (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497

    Google Scholar 

  18. Petitti DB, Kipp H (1986) The leukocyte count: associations with intensity of smoking and persistence of effect after quitting. Am J Epidemiol 123(1): 89–95

    PubMed  CAS  Google Scholar 

  19. Rodgers R, Latif Z, Copland M (2012) How I manage priapism in chronicmyeloid leukaemia patients. Br J Haematol 158(2): 155–164

    Article  PubMed  CAS  Google Scholar 

  20. Rowley J (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290–293

    Article  PubMed  CAS  Google Scholar 

  21. Shtivelman E, Lifshitz B, Gale R, Canaani E (1985) Fused transcript of ABL and BCR genes in chronic myelogenous leukaemia. Nature 315: 550–554

    Article  PubMed  CAS  Google Scholar 

  22. Sokal JE, Cox EB, Baccarani M, et al. (1994) Prognostic discrimination in “ good-risk” chronic granulocytic leukemia. Blood 63: 789–799

    Google Scholar 

  23. Swerdlow S, Campo E, Harris NL, et al. (2008) WHO (World Health Organization) Classification of Tumours of Haematopoietic and Lymphoid Tissue. International Agency for Research on Cancer

  24. Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22(1): 14–22

    Article  PubMed  CAS  Google Scholar 

  25. van Dongen J, Macintyre E, Gabert J, et al. (1999): Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13: 1901–1928

    Article  PubMed  Google Scholar 

  26. Vardiman J, Thiele J, Arber D, et al. (2009): The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937–951

    Article  PubMed  CAS  Google Scholar 

  27. Vlaanderen J, Lan Q, Kromhout H, et al. (2012) Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med 55(9): 779–785

    Article  PubMed  CAS  Google Scholar 

  28. Weerkamp F, Dekking E, Ng Y, et al. (2009) Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients. Leukemia 23: 1106–1117

    Article  PubMed  CAS  Google Scholar 

  29. Young JA (2011) Epidemiology and management of infectious complications in contemporary management of chronic leukemias. Infect Disord Drug Targets 11(1):3–10

    Article  PubMed  CAS  Google Scholar 

Référence électronique

  1. http://www.leukemia-net.org/content/leukemias/cml/cml_score/

Download references

Author information

Authors and Affiliations

  1. Laboratoire central d’hématologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, F-75475, Paris cedex 10, France

    J. -M. Cayuela

  2. Service d’hématologie, CHU Purpan, 1, place du Docteur-Baylac, F-31000, Toulouse, France

    F. Huguet

Authors
  1. J. -M. Cayuela
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Huguet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. -M. Cayuela.

About this article

Cite this article

Cayuela, J.M., Huguet, F. Le diagnostic de la leucémie myéloïde chronique (LMC) en 2012. Oncologie 14, 561–568 (2012). https://doi.org/10.1007/s10269-012-2211-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-012-2211-4

Keywords

Mots clés

Search

Navigation